On September 29, Chutian Technology replied to investors on the interactive platform, "In response to the rise in raw material prices, on the one hand, the company will transfer some of its influence to the downstream industry, on the other hand, the company will strengthen operation and management, reduce costs and increase efficiency
.
" ”
Rising raw material prices, how should pharmaceutical machinery companies respond? (Image source: Pharmaceutical Network)
Raw materials are the upstream part of the pharmaceutical equipment industry, and its price rise will be transmitted to the downstream, bringing pressure to the cost control ability of pharmaceutical machine enterprises, and many enterprises are affected by this, and the performance and gross profit margin have undergone certain changes
.
For example, Canaan Technology replied to investors on the investor relations platform on June 28, "The rise in raw material prices and labor costs have also led to changes in
gross profit margins.
" ”
In February, Canaan Technology also mentioned in the disclosure of the 2021 performance report that due to factors such as rising raw material prices and fierce competition in the downstream industry, the business development of the intelligent warehousing and logistics system sector was less than expected, resulting in a large gap between
the cumulative net profit of the company's holding subsidiary Canaan Feiqi and the performance commitment.
Under the background of rising raw material prices and rising labor costs year by year, pharmaceutical equipment companies are undoubtedly facing challenges in cost control, and how to reduce costs and increase efficiency has become a major issue
that enterprises need to deal with.
It is understood that the level of operation and management of traditional pharmaceutical equipment enterprises is generally low, mostly based on extensive management, the phenomenon of waste of resources is more serious, the production efficiency is not high, resulting in relatively high
costs.
Therefore, in order to cope with the challenge of rising raw material prices, pharmaceutical machinery enterprises should strengthen their operation and management, change from extensive to lean management mode, reduce costs, improve quality, speed up processes and improve capital investment, so as to achieve greater value
.
According to the definition, lean management originates from lean production, which has gradually extended to the management business of the enterprise and has gradually risen to the strategic management concept
.
In recent years, the concept of "lean management" has gradually become deeply popularized in the field of pharmaceutical equipment, and has been learned and absorbed by more and more enterprises, accelerating the pace
of upgrading.
For example, some pharmaceutical machinery enterprises will hold a series of courses on lean production management to let employees understand the core values of lean production management system, effectively identify and eliminate waste in the production and management process, reduce enterprise costs, and improve the level of
enterprise management refinement and digitalization.
Through the course training combined with the actual situation of the enterprise, let employees understand lean production, so that it can avoid waste in the future work process, reduce costs, improve efficiency, and bring benefits
to the enterprise.
There are also pharmaceutical machinery enterprises through the establishment of their own lean production management system, including modular design concept, rigorous material procurement control, refined production and processing, multi-level quality control center, rapid response service, etc.
, so that enterprises can be professional, standardized development
.
With the advent of the era of intelligent manufacturing, the entire manufacturing industry is accelerating in the wave of digitalization, and more and more pharmaceutical machine companies have begun to join the tide of digital transformation, gradually realizing lean management and lean production through the implementation of modern management in order to achieve greater benefits
.
It is reported that Dongfulong, as an active practitioner of intelligent manufacturing, is actively transforming
around intelligent manufacturing and digitalization.
In July this year, Dongfulong proposed to raise no more than 3.
2 billion yuan was approved by the Shenzhen Stock Exchange, it is reported that the fundraising project will be equipped with superior performance of production equipment to meet the needs of automated and intelligent production, while giving play to location advantages, cost reduction and efficiency, strengthen the company's supply capacity, form a good synergy with the existing production base, and enhance the company's comprehensive strength
.
In addition, in the current situation of fierce homogenization competition, the industry believes that pharmaceutical machinery companies also need to increase investment in research and development, actively explore and promote product upgrading, improve product quality and performance, and thus improve the competitiveness
of enterprises themselves.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
